Overview of Dr. Varghese
Dr. Anna Varghese is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from Case Western Reserve University School of Medicine and has been in practice 11 years. She is one of 494 doctors at Memorial Sloan Kettering Cancer Center and one of 90 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. She has more than 60 publications and over 500 citings.
Office
160 East 53rd Street
New York, NY 10022
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2006 - 2009
Case Western Reserve University School of MedicineClass of 2006
Certifications & Licensure
FL State Medical License 2021 - Present
CT State Medical License 2023 - 2025
NJ State Medical License 2009 - 2025
NY State Medical License 2010 - 2025
NH State Medical License 2024 - 2024
NC State Medical License 2020 - 2022
MA State Medical License 2009 - 2011- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer Start of enrollment: 2016 Jun 15
- Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer Start of enrollment: 2020 Jul 01
- A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer Start of enrollment: 2018 Mar 07
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 66 citationsTherapeutic Implications of Germline Testing in Patients With Advanced Cancers.Zsofia K. Stadler, Anna Maio, Debyani Chakravarty, Yelena Kemel, Margaret Sheehan
Journal of Clinical Oncology. 2021-06-16 - 251 citationsGenomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.Bastien Nguyen, Christopher Fong, Anisha Luthra, Shaleigh A Smith, Renzo G DiNatale
Cell. 2022-02-03 - 853 citationsMutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.Ahmet Zehir, Ryma Benayed, Ronak H Shah, Aijazuddin Syed, Sumit Middha
Nature Medicine. 2017-06-01
Lectures
- Young-onset pancreas cancer (PC) in patients less than or equal to 50 years old at Memorial Sloan Kettering (MSK): Descriptors, genomics, and outcomes.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations.2019 ASCO Annual Meeting - 6/1/2019
- A phase I expansion study of trifluridine and tipiracil (FTD/TPI) in combination with irinotecan (IRI) and bevacizumab (BEV) in patients with metastatic colorectal can...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
